IntelliPharmaCeutics' (NASDAQ:IPCI) shares were weak (-5%) on the heels of disappointing data from Acura Pharmaceuticals (NASDAQ:ACUR) [which was down -20% on the news] for a product ostensibly similar to its Rexista technology. The stock could potentially decline some more as investors digest the news over the next few days, which I believe could be a compelling buying opportunity. The stock has been thinly covered on this Board, and the latest action may prompt some to revisit the story.
First, Some Brief Background
IntelliPharmaCeutics International Inc. (IPCI) is a pharmaceutical company specializing in the research, development and manufacture of generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technologies are a multidimensional controlled-release...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|